Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis.
Taylor D SteuberThomas RosandichTiffany CadwalladerLauren SteilMadeline BelkUsha YendrapalliAli HassounJonathan EdwardsPublished in: The Annals of pharmacotherapy (2023)
In this retrospective study involving hospitalized patients with COVID-19, there was no difference between tocilizumab 162 mg SC and 400 mg IV in terms of efficacy. The 162 mg SC dose may be a reasonable alternative to traditional doses.